Pfizer Continues Pipeline Cuts with Another Seagen Cancer Drug Drop
Summary:
Pfizer has discontinued an early-stage antibody-drug conjugate, PF-08046031, originally acquired through its Seagen deal, citing business reasons rather than safety concerns. The move adds to a series of recent pipeline cuts from the Seagen portfolio, reflecting ongoing strategic pruning despite earlier signals that major reductions were largely complete.
First Organoid-Based Regenerative Therapy Enters Clinical Trials for Crohn’s Disease
Summary:
OrganoidSciences has received IND approval to begin a Phase 1 trial of ATORM-C, an autologous intestinal organoid therapy designed to regenerate damaged tissue in patients with Crohn’s disease. Marking a global first, the therapy will be tested for safety and early efficacy, offering a novel regenerative approach for patients with treatment-resistant intestinal ulcers.
Women’s Health Market Poised to Reach $600B by 2030
Summary:
A new report from PwC estimates the global women’s health sector could grow to $600 billion by 2030, driven by expanding definitions of care, rising investment, and innovation in digital and consumer health models. Despite currently receiving only about 5% of healthcare R&D funding, the sector presents a major untapped opportunity, especially in areas like oncology, menopause, and underdiagnosed conditions.
Excalipoint Launches with $69M to Advance Next-Gen T Cell Engagers
Summary:
Excalipoint Therapeutics raised $68.7 million to develop a pipeline of multifunctional T cell engager antibodies for cancer and autoimmune diseases, with early clinical programs already underway. The company’s trispecific and “masked” antibody designs aim to improve efficacy in solid tumors while reducing side effects, positioning them as potential advances over current immunotherapies.
Retatrutide Shows Strong Diabetes and Weight Loss Results in Phase 3 Trial
Summary:
Eli Lilly’s triple-acting drug retatrutide met Phase 3 goals in Type 2 diabetes patients, significantly reducing blood sugar and body weight, with up to 15% weight loss over 40 weeks. Targeting GLP-1, GIP, and glucagon, the drug may outperform existing treatments like tirzepatide and emerge as a highly potent option for obesity and metabolic disease.
